| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT05139004) | City of Hope Medical Center | 2022-07-19 |
| Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms (NCT05455294) | Jacqueline Garcia, MD | 2022-07-18 |
| Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) (NCT05233618) | Karen Ballen, MD | 2022-07-13 |
| A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS (NCT05448599) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-07-08 |
| Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (NCT05079230) | Gilead Sciences | 2022-07-07 |
| Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia (NCT04982354) | Guenther Koehne | 2022-07-05 |
| Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML (NCT06827899) | The First Affiliated Hospital of Xiamen University | 2022-07-01 |
| Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients (NCT05361057) | Institute of Hematology & Blood Diseases Hospital, China | 2022-06-29 |
| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT05316701) | Orca Biosystems, Inc. | 2022-06-21 |
| A Patient-Centered Communication Tool (UR-GOAL) Versus Usual Care for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists (NCT05335369) | University of Rochester | 2022-06-17 |
| Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia (NCT05445011) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2022-06-14 |
| MargheRITA (Remote Intelligence for Therapeutic Adherence) (NCT05260203) | Advice Pharma Group srl | 2022-06-04 |
| A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (NCT05428969) | Faron Pharmaceuticals Ltd | 2022-06-02 |
| FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia. (NCT05383014) | Assiut University | 2022-06-01 |
| GilteRInf 2022 Study (Gilteritinib Related Infections) (NCT05791890) | University of Rome Tor Vergata | 2022-05-31 |
| Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission (NCT04968015) | French Innovative Leukemia Organisation | 2022-05-25 |
| Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS (NCT05342584) | Montefiore Medical Center | 2022-05-25 |
| Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. (NCT06328179) | Huai'an First People's Hospital | 2022-05-24 |
| Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling (NCT05431257) | Rigshospitalet, Denmark | 2022-05-24 |
| Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia (NCT05356169) | Institute of Hematology & Blood Diseases Hospital, China | 2022-05-19 |
| A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. (NCT05155709) | Novartis Pharmaceuticals | 2022-05-17 |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (NCT04771572) | Newave Pharmaceutical Inc | 2022-05-08 |
| Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (NCT04676243) | University Hospital Heidelberg | 2022-05-01 |
| Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients (NCT05433532) | The First Affiliated Hospital of Soochow University | 2022-05-01 |
| Real World Outcomes Using Novel Agents for AML in the UK (NCT05312112) | Guy's and St Thomas' NHS Foundation Trust | 2022-05-01 |
| Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study" (NCT05304156) | Assistance Publique - Hôpitaux de Paris | 2022-04-26 |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study (NCT04726241) | PedAL BCU, LLC | 2022-04-18 |
| Off-the-shelf NK Cells + SCT for Myeloid Malignancies (NCT05115630) | M.D. Anderson Cancer Center | 2022-04-08 |
| COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT03595787) | Institut Paoli-Calmettes | 2022-04-04 |
| Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3). (NCT07561892) | Fujian Medical University Union Hospital | 2022-04-01 |
| Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia (NCT04885127) | Stanford University | 2022-03-30 |
| The Patient Cohort of the National Center for Precision Medicine in Leukemia (NCT05326919) | Assistance Publique - Hôpitaux de Paris | 2022-03-28 |
| Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm (NCT04992949) | French Innovative Leukemia Organisation | 2022-03-23 |
| Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive Chemotherapy (NCT05249894) | A.O.U. Città della Salute e della Scienza | 2022-03-23 |
| Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML (NCT05184842) | Montefiore Medical Center | 2022-03-23 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (NCT05107856) | Prelude Therapeutics | 2022-03-22 |
| Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT (NCT05015426) | H. Lee Moffitt Cancer Center and Research Institute | 2022-03-21 |
| Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (NCT05275439) | Shattuck Labs, Inc. | 2022-03-17 |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (NCT05279859) | Erasca, Inc. | 2022-03-15 |
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia (NCT05326516) | Syndax Pharmaceuticals | 2022-03-09 |
| Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission (NCT04914676) | University of Florida | 2022-03-08 |
| Cardioprotection in AML (NCT04977180) | University of Virginia | 2022-03-04 |
| Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia (NCT04867928) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2022-03-01 |
| Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia (NCT05248685) | Beijing Boren Hospital | 2022-02-16 |
| Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) (NCT05223699) | Magenta Therapeutics, Inc. | 2022-02-14 |
| Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML (NCT05503134) | Nationwide Children's Hospital | 2022-02-14 |
| Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients (NCT04817241) | National Cancer Institute (NCI) | 2022-02-10 |
| Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure (NCT04905810) | Brian Jonas | 2022-02-09 |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (NCT04797767) | University of Washington | 2022-02-04 |
| XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia (NCT05038644) | Ehab L Atallah | 2022-02-02 |
| Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms (NCT04902833) | Massachusetts General Hospital | 2022-02-01 |
| A Study of BTX-1188 in Subjects With Advanced Malignancies (NCT05144334) | Biotheryx, Inc. | 2022-01-24 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330) | Biomea Fusion Inc. | 2022-01-24 |
| Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients (NCT06162325) | Peking Union Medical College Hospital | 2022-01-21 |
| Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial (NCT05382390) | Huihan Wang | 2022-01-21 |
| Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study (NCT05258799) | Huihan Wang | 2022-01-21 |
| Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT (NCT05823714) | The First Affiliated Hospital of Soochow University | 2022-01-20 |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission (NCT05197426) | Bristol-Myers Squibb | 2022-01-17 |
| CPX-351 Real-World Effectiveness and Safety Study (NCT05169307) | Jazz Pharmaceuticals | 2022-01-14 |
| A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies (NCT04937166) | Kahr Medical | 2022-01-13 |
| A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT05140811) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-01-05 |
| FLT3 Clonal Evolution in Patients With Acute Myeloid Leukemia (NCT06463639) | National Taiwan University Hospital | 2022-01-01 |
| Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia (NCT05023707) | The First Affiliated Hospital of Soochow University | 2021-12-31 |
| A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia (NCT04822766) | Assistance Publique - Hôpitaux de Paris | 2021-12-31 |
| A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies (NCT05055791) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-12-29 |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets (NCT05215639) | AbbVie | 2021-12-27 |
| Acute Myeloid Leukemia Registry (NCT05979675) | Turkish Hematology Association | 2021-12-21 |
| Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia (NCT05066165) | Intellia Therapeutics | 2021-12-17 |
| Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment (NCT04953897) | Taiho Oncology, Inc. | 2021-12-15 |
| Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (NCT05266950) | Beijing Boren Hospital | 2021-12-13 |
| Latin American Real-world Study in Acute Leukemia (NCT05166135) | Pfizer | 2021-12-10 |
| Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax (NCT04763928) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2021-12-03 |
| PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML (NCT05105152) | Seattle Children's Hospital | 2021-11-29 |
| CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases (NCT04662294) | Zhejiang University | 2021-11-18 |
| Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia (NCT05042531) | LanZhou University | 2021-11-13 |
| Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML (NCT06536010) | Yang Xiaotian | 2021-11-03 |
| FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia (NCT04714372) | Masonic Cancer Center, University of Minnesota | 2021-11-03 |
| Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML (NCT05334693) | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | 2021-11-01 |
| Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies (NCT05123352) | The First Affiliated Hospital of Soochow University | 2021-11-01 |
| Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML (NCT05272293) | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | 2021-11-01 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission (NCT05010772) | M.D. Anderson Cancer Center | 2021-10-25 |
| A Patient-centered Communication Tool (UR-GOAL) for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists (NCT04625413) | University of Rochester | 2021-10-23 |
| Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS (NCT04708054) | M.D. Anderson Cancer Center | 2021-10-21 |
| Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML (NCT05053425) | LanZhou University | 2021-10-20 |
| Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings (NCT04969601) | Assistance Publique - Hôpitaux de Paris | 2021-09-29 |
| 2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML (NCT04953780) | West Virginia University | 2021-09-27 |
| Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS (NCT04986657) | Washington University School of Medicine | 2021-09-17 |
| Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT (NCT05066958) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2021-09-16 |
| A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (NCT05061147) | Maxinovel Pty., Ltd. | 2021-09-16 |
| Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia (NCT04923919) | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 2021-09-14 |
| Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. (NCT04623216) | Novartis Pharmaceuticals | 2021-09-14 |
| Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT (NCT04764513) | Chinese PLA General Hospital | 2021-09-12 |
| New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT05029141) | The First Affiliated Hospital of Soochow University | 2021-09-01 |
| KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia (NCT04914845) | University of Colorado, Denver | 2021-08-27 |
| Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT04905407) | Syros Pharmaceuticals | 2021-08-26 |
| Backtracking Leukemia-Typical Somatic Mutations in Cord Blood (NCT05014165) | Children's Oncology Group | 2021-08-25 |
| Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant (NCT04836390) | Michael Pulsipher | 2021-08-24 |
| Study of GDX012 in Patients With MRD Positive AML (NCT05001451) | GammaDelta Therapeutics Limited | 2021-08-13 |
| A Study of E7820 in People With Bone Marrow (Myeloid) Cancers (NCT05024994) | Memorial Sloan Kettering Cancer Center | 2021-08-13 |